Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3539978 | 0.98 | CYP11B2 (0.97) | CYP11B2HTR2CIDO1ALDH1A1KDM4E | |
| SCHEMBL3540598 | 0.79 | CYP11B2 (0.65) | CYP11B2IDO1ALDH1A1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL3535788 | 0.77 | CYP11B2 (0.63) | CYP11B2IDO1ALDH1A1KDM4EMAPT | |
| SCHEMBL3534134 | 0.76 | CYP11B2 (0.61) | CYP11B2TBXAS1CYP11B1 | |
| SCHEMBL9261340 | 0.75 | CYP11B2 (0.60) | CYP11B2IDO1TBXAS1 | |
| Hydrochloric Acid SCHEMBL3534828 | 0.75 | CYP11B2 (0.59) | CYP11B2TBXAS1CYP11B1 | |
| SCHEMBL3710027 | 0.73 | HTR2C (0.61) | CYP11B2HTR2CIDO1KDM4E | |
| SCHEMBL27794063 | 0.73 | CYP11B2 (0.58) | CYP11B2HTR2CIDO1ALDH1A1KDM4E | |
| SCHEMBL27794035 | 0.73 | CYP11B2 (0.58) | CYP11B2HTR2CIDO1ALDH1A1KDM4E | |
| SCHEMBL3536508 | 0.71 | CYP11B2 (0.55) | CYP11B2IDO1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | claimed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | claimed |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2007-08-23 | — | — | US | claimed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | claimed |
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2006-03-16 | — | — | US | claimed |
| JP-2006508970-A | — | — | 2006-03-16 | — | — | JP | claimed |
| EP-1565463-A1 | IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | Novartis AG (CH) | 2005-08-24 | — | — | EP | claimed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | claimed |
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | disclosed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | disclosed |
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2006-03-16 | — | — | US | disclosed |
| EP-1565463-A1 | IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | Novartis AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | CYP11B1, CYP17A1, CYP27A1 | CYP11B2 8/4885HTR2C 3827/4885IDO1 695/4885 |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | CYP11B1, CYP27A1, CYP17A1 | CYP11B2 7/4885HTR2C 3754/4885IDO1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.